Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | LIFR | P42702 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3996233 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29354246 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL14601398 | 0.95 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491489 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491490 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL12932245 | 0.90 | NR1H4 (0.81) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL5354375 | 0.89 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16448984 | 0.88 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL13805380 | 0.88 | NR1H4 (0.79) | NR1H4MEN1FABP1THRBLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599648-B2 | Pharmaceutical composition comprising a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain fatty acid or prodrug thereof | OCVIRK SOEREN (DE) | 2026-04-14 | — | — | US | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| US-20240335497-A1 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2024-10-10 | — | — | US | claimed |
| EP-4376865-A2 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2024-06-05 | — | — | EP | claimed |
| EP-4171600-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK, Sören (DE) | 2023-05-03 | — | — | EP | claimed |
| CN-116056719-A | Pharmaceutical composition comprising a combination of guanylate cyclase C (GUCY 2C) agonist and a short chain fatty acid or prodrug thereof | 索伦·欧克维克 | 2023-05-02 | — | — | CN | claimed |
| EP-4135691-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-02-22 | — | — | EP | claimed |
| WO-2023006248-A2 | METHOD FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2023-02-02 | — | — | WO | claimed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-115397412-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250057975-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-02-20 | — | — | US | disclosed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023006248-A2 | METHOD FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2023-02-02 | — | — | WO | disclosed |
| CN-115397412-A | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115335055-A | Pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis | 东亚ST株式会社 | 2022-11-11 | — | — | CN | disclosed |
| CN-109310727-B | Conditionally active heterodimeric polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2022-09-27 | — | — | CN | disclosed |
| US-20220241376-A1 | METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON | ENYO PHARMA (FR) | 2022-08-04 | — | — | US | disclosed |
| WO-2022061008-A2 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057975-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | CD44, PGF, SLC46A1 | NR1H4 1214/4885MEN1 3422/4885FABP1 526/4885 |
| US-20220241376-A1 | METHOD FOR DECREASING ADVERSE-EFFECTS OF INTERFERON | IFNG, IFNAR1, IRF3 | NR1H4 1756/4885MEN1 4152/4885FABP1 244/4885 |
| US-12599648-B2 | Pharmaceutical composition comprising a combination of a guanylate cyclase C (GUCY2C) agonist and a short-chain fatty acid or prodrug thereof | GUCY1B2, GUCY1A2, GUCY1B1 | NR1H4 133/4885MEN1 2924/4885FABP1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.